By Matthew Pillar, Editor, BioProcess Online
In virtually any market, an eight-to-10-year CAGR forecast between 5%and 10%is good. Twenty percent is great. Thirty percent is stellar.
Coherent Market Research pegs the oral biologics market to grow at a CAGR of more than 35% through 2028.
But the mouth isn’t the only alternative approach to biologic vaccine and therapeutic administration, and tablets and capsules aren’t the only formulations making waves. The nasal epithelium presents an increasingly promising site of administration of large molecules. That’s a partial driver of the analyst expectations that the intranasal drug delivery market will hit $71.3 billion by 2026 (per Global Industry Analysts Inc.).